Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Evommune (EVMN) Other Working Capital Changes (2024 - 2026)

Evommune (EVMN) reported Other Working Capital Changes of $85000.0 for Q1 2026, up 102.83% year-over-year from $41906.3 in Q1 2025, and down 77.15% on a QoQ basis from $372000.0 in Q4 2025.

Evommune (EVMN) has 3 years of Other Working Capital Changes data on file, last reported at $85000.0 in Q1 2026.

  • Quarterly Other Working Capital Changes rose 102.83% year-over-year to $85000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.8 million (changed N/A YoY) and the FY2025 annual result came in at $2.4 million, up 133.04% from the prior year.
  • Other Working Capital Changes retreated to $85000.0 in Q1 2026 per EVMN's latest filing, from $372000.0 in the prior quarter.
  • Across five years, Other Working Capital Changes topped out at $706000.0 in Q4 2024 and bottomed at -$3.0 million in Q1 2025.
  • The 3-year median for Other Working Capital Changes is $228500.0 (2025), against an average of -$459250.0.
  • The widest annual swing landed in 2025, when Other Working Capital Changes sank 47.31%; it then soared 102.83% in 2026.
  • Tracing EVMN's Other Working Capital Changes over 3 years: stood at $706000.0 in 2024, then slumped by 47.31% to $372000.0 in 2025, then sank by 77.15% to $85000.0 in 2026.
  • Per Business Quant, the three latest EVMN Other Working Capital Changes figures stand at $85000.0 (Q1 2026), $372000.0 (Q4 2025), and -$3.0 million (Q1 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn
7 Evaxion A 62.56 Bn 62.54 Bn -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn
10 Evommune 744.11 Mn 532.65 Mn -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 85,000.00
Mar 31, 2026 85,000.00
Dec 31, 2025 372,000.00
Dec 31, 2025 372,000.00
Mar 31, 2025 -3.00 Mn
Mar 31, 2025 -3.00 Mn
Dec 31, 2024 706,000.00
Dec 31, 2024 706,000.00